Last reviewed · How we verify
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| VERDYE powder for solution for injection 25 mg | VERDYE powder for solution for injection 25 mg | marketed | ||||
| Autologous MSCs | Autologous MSCs | phase 3 | Cell therapy | Regenerative Medicine / Orthopedics | ||
| Allogenic MSCs | Allogenic MSCs | phase 3 | Cell therapy | Regenerative Medicine / Immunology |
Therapeutic area mix
- Regenerative Medicine / Immunology · 1
- Regenerative Medicine / Orthopedics · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Biosolution Co., Ltd. · 1 shared drug class
- Bone Therapeutics S.A · 1 shared drug class
- Brainstorm-Cell Therapeutics · 1 shared drug class
- Celavie Bioscences, LLC · 1 shared drug class
- China Spinal Cord Injury Network · 1 shared drug class
- City of Hope Medical Center · 1 shared drug class
- DiscGenics, Inc. · 1 shared drug class
- Avicenna Research Institute · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León:
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León pipeline updates — RSS
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León pipeline updates — Atom
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-instituto-de-estudios-de-ciencias-de-la-salud-de-castilla-y-le-n. Accessed 2026-05-17.